Streetbeat News

Price Targets

COCO

Piper Sandler analyst Michael Lavery maintains an Overweight rating on Vita Coco (NASDAQ:COCO) and raises the price target from $32 to $35.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:52 pm

RGEN

RBC Capital analyst Conor McNamara has maintained an 'Outperform' rating on Repligen (NASDAQ:RGEN) but lowered the price target from $207 to $200.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:52 pm

HMST

Piper Sandler analyst Matthew Clark maintains a Neutral rating on HomeStreet (NASDAQ:HMST) and lowers the price target from $8 to $5.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:50 pm

PCH

RBC Capital analyst Paul Quinn has maintained a 'Sector Perform' rating on PotlatchDeltic (NASDAQ:PCH) and lowered the price target from $52 to $48.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:49 pm

LEG

Piper Sandler analyst Peter Keith maintains an Underweight rating on Leggett & Platt (NYSE:LEG) and lowers the price target from $21 to $18.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:48 pm

NBIX

RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Neurocrine Biosciences (NASDAQ:NBIX) and raised the price target from $123 to $128.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:47 pm

NBIX

Piper Sandler analyst David Amsellem maintains a Neutral rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $95 to $100.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:46 pm

XYL

RBC Capital analyst Deane Dray has maintained an 'Outperform' rating on Xylem (NYSE:XYL) but lowered the price target from $123 to $120.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:45 pm

VNO

Piper Sandler analyst Alexander Goldfarb maintains an Underweight rating on Vornado Realty (NYSE:VNO) and has lowered the price target from $17 to $16.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:44 pm

MSCI

RBC Capital analyst Ashish Sabadra has reiterated an Outperform rating on MSCI (NYSE:MSCI) and maintained a price target of $570.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:43 pm